Nusano is a privately-held medical technology company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. Nusano’s production platform combines time-proven technology from universities and world-class research centers with the company’s patented particle acceleration technology. The result is the first significant advancement in radioisotope production in decades – a platform that’s smaller, safer and more efficient than existing methods, capable of the simultaneous manufacturing of multiple radioisotopes needed for advanced pharmaceuticals, treatments and procedures.

Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company intends to develop multiple products through clinical proof-of-concept and potentially through Accelerated Approval in the United States. For more information, please visit www.vincerx.com.

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and a Phase 1 study. Cortexyme is initiating a Phase 2 of its lead small molecule COR-388 in 2019. Cortexyme was founded based upon the seminal discovery by Dr. Stephen Dominy of pathogenic bacteria in the brain of Alzheimer's patients. Infection of mice with the same bacteria results in brain infiltration, neurodegeneration and other pathology of Alzheimer's. Because the bacteria is persistent and resistant to broad spectrum antibiotics, Cortexyme has developed small molecules to stop disease progression.

Innventus Fund completed a 1st close in 2018, targeted assets under management is $150M for the fund. We partner with Fortune 100 companies to commercialize innovative technologies to transform markets.Our strategy is to partner with multinational corporations and institutional innovators, becoming their premier systematic value creation engine. Procter & Gamble is our initial partner. Our unique relationships provide access to their innovative technologies and built-in customer channels — enabling us to identify opportunities with the highest potential — while lessening the many inherent risks to more conventional start-ups.

FLG Partners is the premier solution for comprehensive board advisory and CFO consulting services for Silicon Valley companies, ranging from A-round to billion dollar public companies. While nearly all our clients have Silicon Valley roots, many of the investors in our clients invest around the world. As a result, our clients extend far beyond Silicon Valley.SENTREHEARTSentreHEART is focused on remote suture delivery for immediate and complete closure of anatomic structures. For decades, clinicians have been using suture for anatomic closure, but due to technique and operator variability, the results are frequently sub-optimal. The LARIAT Suture Delivery Device enables clinicians to precisely deliver a pre-tied suture loop to the ideal location for closure and reduces the likelihood of leaks or gaps due to operator variability.AMUNIX (PAST CLIENT)Amunix is an industry leader in the discovery and development of long-acting protein-based therapeutics. Amunix’ pipeline products are based on our proprietary XTEN® half-life extension, Antibody-XTEN-Drug Conjugate and ProTIA pro-drug, bispecific T-cell engager platform technologies. Amunix is applying these technologies over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing. The company is actively engaged in both a diverse array of internal product development efforts as well as ongoing collaborations with leading biotechnology and pharma companies.SKINCENTIAL SCIENCES (PAST CLIENT)Skincential Sciences™ began with a desire to fuse skincare solutions with forward-thinking technology.

Inspyr Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of promising, new therapeutics. Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.Mipsagargin, our lead agent, is in human clinical trials for patients with several different tumor types:-Hepatocellular carcinoma, or liver cancer-Glioblastoma, or brain cancer-Prostate cancerOur experienced and motivated team has deep pharmaceutical industry and scientific experience:Both the management team and board of directors have extensive experience in bringing new treatments from discovery to development.Our cutting-edge platform technology has the potential to work across a spectrum of drugs that precisely target different cancers. We are boldly pursuing the opportunities found within our research, expanding our technology platform to design treatments for other clinical indications.Inspyr has a strong intellectual property portfolio and has been granted orphan drug status by the U.S. Food and Drug Administration for its lead agent.

EpiBiome is a precision microbiome engineering company whose mission is to surveil bacterial populations and to develop effective and sustainable FDA-approved therapies to combat infectious diseases in humans and in agriculture without the use of shared-class antibiotics. Instead of antibiotics, the company deploys non-GMO, bacteria-specific viruses, abundant in nature and harmless to humans, to address problematic bacteria.

Chief Executive Officer - February 2014 - PresentChairman of Audit CommitteeChairman of Compensation Committee